Know Cancer

or
forgot password

Occurrence of Brain Metastasis in Breast Cancer Patients Diagnosed at Advanced Stages of the Disease


N/A
30 Years
N/A
Open (Enrolling)
Female
Cancer

Thank you

Trial Information

Occurrence of Brain Metastasis in Breast Cancer Patients Diagnosed at Advanced Stages of the Disease


A retrospective cohort study will be conducted in the Henry Ford Health System (HFHS). Using
medical record review, we will identify all women diagnosed with advanced stage (stage III
and IV) breast cancer between January 1, 1995- December 31, 2007. For each case included in
the study, we will obtain data on demographics, tumor information, treatment related medical
encounters and procedures, and occurrence and timing of brain and/or other distant
metastases. The main outcome for this study is the development of distant metastases. Each
patient in the cohort will be classified as to the occurrence and date of distant
metastases. Metastases will be classified as Brain, Distant lymph node, Lung/pleural
effusion, Liver, Bone, Other visceral, Other non-visceral.

Other secondary outcomes to be explored include:

- Survival after advanced breast cancer—time in months from the date of advanced stage
breast cancer diagnosis until death or end of study period

- Time to brain metastases—time in month from the date of advanced stage breast cancer
diagnosis until brain metastases diagnosis

- Survival after brain metastases—time in months from the date of diagnosis of brain
metastases until death or end of study period


Inclusion Criteria:



- Initially diagnosed with American Joint Commission on Cancer (AJCC) stage III or
stage IV breast cancer between January 1, 1995 through December 31, 2007 -OR-
diagnosed with AJCC stage I or II breast cancer and progressed to stage III or IV
disease between January 1, 1995 through December 31, 2007;

- At least one year of follow-up after initial diagnosis (among patients who did not
die before one year of follow-up); and

- Age 30 years or older at diagnosis.

Exclusion Criteria:

- Does not have at least one year of follow-up after initial diagnosis (among patients
who did not die before one year of follow-up); and

- Age less than 30 years or older at diagnosis.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Proportion of advanced stage breast cancer patients that develop brain metastases, overall and stratified by anti-HER2 therapy (for HER2+ patients only).

Outcome Time Frame:

Time from breast cancer diagnosis until death or end of study periods (September 1, 2009)

Safety Issue:

No

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United Kingdom: GSK Observational Study

Study ID:

112951

NCT ID:

NCT01077648

Start Date:

February 2010

Completion Date:

June 2013

Related Keywords:

  • Cancer
  • Breast Cancer
  • Treatment
  • Brain metastases
  • ErbB2 expression
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Brain Neoplasms

Name

Location